A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)

被引：1
|
作者：
Cheng, Y. [1 ]
Qin, Z. [2 ]
Meng, X. [3 ]
Xu, F. [4 ]
Wang, Y. [5 ]
Yao, Y. [6 ]
Fang, J. [7 ]
Zhao, Y. [8 ]
机构：
[1] Jilin Canc Hosp, Med Oncol, Changchun, Peoples R China
[2] Zhejiang Prov Peoples Hosp, Med Oncol, Hangzhou, Peoples R China
[3] Shandong Canc Hosp, Radiat Oncol, Jinan, Peoples R China
[4] Nanchang Univ, Resp Med, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China
[5] Harbin Med Univ, Resp Med, Canc Hosp, Harbin, Heilongjiang, Peoples R China
[6] Xi An Jiao Tong Univ, Med Oncol, Affiliated Hosp 1, Xian, Peoples R China
[7] Peking Univ, Thorac Med Oncol, Canc Hosp, Beijing, Peoples R China
[8] Henan Canc Hosp, Resp Med, Zhengzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1223
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1992P
引用
收藏
页码：S1062 / S1062
页数：1
相关论文
共 50 条
  • [41] Biweekly paclitaxel as second-line treatment in advanced non-small-cell-lung-cancer (NSCLC).: A phase II study of the Galician Lung Cancer Group
    Vazquez-Estevez, S.
    Firvida, J. L.
    Grande, C.
    Baron, F.
    Lazaro, M.
    Salgado, M.
    Campos, B.
    Casal, J.
    Perez, E.
    Mel, J. R.
    EJC SUPPLEMENTS, 2007, 5 (04): : 392 - 392
  • [42] A Phase II Study of KN046 (Bispecific Anti-PD-L1/CTLA-4) in Patients (pts) with Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Zhou, C.
    Xiong, A.
    Li, W.
    Ma, Z.
    Li, X.
    Fang, J.
    Xie, Q.
    Fan, Y.
    Xu, J.
    Van, H.
    Kong, P.
    Yang, F.
    Li, J.
    Lu, Y.
    Xu, T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S636 - S636
  • [43] Phase II study of cabazitaxel as second-line therapy in stage IV non-small cell lung cancer (NSCLC).
    Das, Devika
    Robert, Francisco
    Bordoni, Rodolfo
    Grant, Stefan C.
    Saleh, Mansoor N.
    Reddy, Vishnu
    Jerome, Mary
    Miley, Debi
    Singh, Karen P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer
    Rhee, Chin Kook
    Lee, Sang Haak
    Kim, Ju Sang
    Kim, Seung Joon
    Kim, Seok Chan
    Kim, Young Kyoon
    Kang, Hyun Hee
    Yoon, Hyoung Kyu
    Song, Jeong Sup
    Moon, Hwa Sik
    Kim, Jin Woo
    Kim, Chi Hong
    Shim, Byoung Yong
    Kim, Hoon Kyo
    Sun, Der Sheng
    Kim, Kwan Hyoung
    LUNG CANCER, 2011, 72 (01) : 64 - 67
  • [45] Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer
    Ettinger, David S.
    Jotte, Robert
    Lorigan, Paul
    Gupta, Vicram
    Garbo, Lawrence
    Alemany, Carlos
    Conkling, Paul
    Spigel, David R.
    Dudek, Arkadiusz Z.
    Shah, Chirag
    Salgia, Ravi
    McNally, Richard
    Renschler, Markus F.
    Oliver, Jennifer W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15) : 2598 - 2603
  • [46] A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second-line treatment in advanced small cell lung cancer
    Xu, Yinghui
    Wang, Xu
    Sun, Chao
    Gao, Zhiru
    He, Hua
    Qiu, Shi
    Guo, Ye
    Ma, Xiaohui
    Song, Junya
    Ma, Kewei
    CANCER MEDICINE, 2023, 12 (03): : 2979 - 2989
  • [47] KEYNOTE-B98: Phase Ib/II study of pembrolizumab plus investigational agents as second-line treatment for anti-PD-1/PD-L1-refractory extensive-stage small cell lung cancer (ES-SCLC)
    Lai, W. C. V.
    Ahn, M-J.
    Shentzer, T.
    Kowalski, D.
    Cho, B. C.
    Schmid, S.
    Jove, M.
    Huang, M.
    Zhao, B.
    El-Osta, H.
    Navarro, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1425 - S1426
  • [48] Combination of Anlotinib and PD-1/PD-L1 Inhibitors as Second-line and Subsequent Therapy in Advanced Small-cell Lung Cancer
    Yu, L.
    Xu, J.
    Qiao, R.
    Zhong, H.
    Han, B.
    Zhong, R.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S391 - S392
  • [49] Low-dose weekly paclitaxel as second-line treatment for advanced non-small cell lung cancer:: a phase II study
    Juan, O
    Albert, A
    Ordoño, F
    Casany, R
    Carañana, V
    Campos, JM
    Alberola, V
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2002, 32 (11) : 449 - 454
  • [50] A phase II study of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed first line treatment
    Zhou, C.
    Xiong, A.
    Fang, J.
    Li, X.
    Fan, Y.
    Zhuang, W.
    Xie, Q.
    Ma, Z.
    Kang, M.
    Xu, T.
    Xu, M.
    Zhi, L.
    Liu, Q.
    Wang, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1022 - S1022
12345